
J Neuropsychiatry Clin Neurosci 18:547-549, November 2006
doi: 10.1176/appi.neuropsych.18.4.547
© 2006 American Neuropsychiatric Association
Clinical and Research Reports |
A Pilot Study of Quetiapine Treatment of Aggression Due to Traumatic Brain Injury
Edward Kim, M.D., M.B.A. and
Mona Bijlani, M.D.
Received September 7, 2005; revised December 6, 2005; accepted December 30, 2005. Dr. Kim is Clinical Associate Professor of Psychiatry, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey, and Associate Director of Neuroscience Medical Strategy, Bristol-Myers Squibb Company, Plainsboro, New Jersey. Dr. Bijlani is Assistant Professor of Psychiatry, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, New Jersey. Address correspondence to Dr. Kim, Associate Professor of Psychiatry, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, 671 Hoes Lane, Piscataway, NJ 08855-1392; edward.kim{at}bms.com (E-mail).
ABSTRACT
In a 6-week open-label, flexible dose pilot study of quetiapine for treatment of aggression secondary to traumatic brain injury (TBI), seven subjects who were at least 3-months post-injury were enrolled. The Overt Aggression Scale Modified (OAS-M) and Clinical Global Impression (CGI) were primary outcome measures. Administration of quetiapine at doses of 25 to 300mg daily was efficacious and well-tolerated in reducing irritability and aggression resulting from TBI, with an associated improvement in cognitive functioning.
Get information about faster international access.
a>
Privacy Policy
Copyright © 2006
American Neuropsychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|